fluralaner fluralaner fluralaner (inn) is a systemic insecticide and acaricide that is administered orally or topically. the u.s. food and drug administration (fda) approved it under the trade name bravecto for flea treatment in dogs in may 2014 and bravecto plus as a topical treatment for cats in november 2019, with warnings about possible side effects in both species. the eu approved the drug in february 2014. australia approved it for the treatment and prevention of ticks and fleas on dogs in january 2015. fluralanerclinical datapronunciation/ˌflʊərəˈlænər/ floor-ə-lan-ər trade namesbravectoother names a1443, ah252723 4--n--o-toluamide license data eu ema: by inn us dailymed: fluralaner routes ofadministrationby mouth (chewable tablets)atcvet codeqp53be02 (who) legal statuslegal status au: s5 (caution) us: ℞-only eu: rx-only rx-only; otc (ru) pharmacokinetic databioavailability20–27%; reduced in the fasted stateelimination half-life9.3–16.2 daysidentifiers iupac name (±)-4--2-methyl-n-benzamide cas number864731-61-3pubchem cid25144319chemspider29398949uniiwsh8393rm5keggd10402chemblchembl2364610comptox dashboard (epa)dtxsid90235581 echa infocard100.215.812 chemical and physical dataformulac22h17cl2f6n3o3molar mass556.29 g·mol−13d model (jsmol)interactive imagechiralityracemic mixture smiles cc1cc(ccc1c(=o)ncc(=o)ncc(f)(f)f)c2=noc(c2)(c3cc(cc(c3)cl)cl)c(f)(f)f inchi inchi=1s/c22h17cl2f6n3o3/c1-11-4-12(2-3-16(11)19(35)31-9-18(34)32-10-21(25,26)27)17-8-20(36-33-17,22(28,29)30)13-5-14(23)7-15(24)6-13/h2-7h,8-10h2,1h3,(h,31,35)(h,32,34)key:mlbzkogamrtskp-uhfffaoysa-n mode of action fluralaner inhibits γ-aminobutyric acid (gaba)-gated chloride channels (gabaa receptors) and l-glutamate-gated chloride channels (glucls). potency of fluralaner is comparable to fipronil (a related gaba-antagonist insecticide and acaricide). research fluralaner is being investigated to determine its ability to reduce the incidence of mosquito-borne diseases as well as bedbugs.